Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neurofibromatosis 1 × cabozantinib × 90 days × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 25 Carcinoma, Hepatocellular 4 Urinary Bladder Neoplasms 3 Urethral Neoplasms 3 Prostatic Neoplasms 3 Osteosarcoma 3 Melanoma 3 Kidney Neoplasms 3 Colorectal Neoplasms 3 Clear-cell metastatic renal cell carcinoma 3 Urogenital Neoplasms 2 Ureteral Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Small Cell Lung Carcinoma 2 Sarcoma, Ewing 2 Penile Neoplasms 2 Ovarian Neoplasms 2 Neuroendocrine Tumors 2 Neoplasm Metastasis 2 Carcinoma, Transitional Cell 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma 2 Brain Neoplasms 2 Adrenocortical Carcinoma 2 von Hippel-Lindau Disease 1 Urologic Neoplasms 1 Urachal adenocarcinoma 1 Triple Negative Breast Neoplasms 1 Seminoma 1 Sarcoma, Kaposi 1

Interventions

AZD 6244 9 trametinib 2 talimogene laherparepvec 1 omipalisib 1 dabrafenib 1 cabozantinib 1 Waiting Lists 1 Vincristine 1 Specimen Handling 1 Magnetic Resonance Spectroscopy 1 Liquid Biopsy 1 Lasers, Solid-State 1 Lasers 1 Curcumin 1 Carboplatin 1 Biopsy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06502171 2026-03-12

NF113

University of Alabama at Birmingham

Phase 1 Not yet recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon ⚡